Bifidobacterium breve M-16V regulates the autonomic nervous system via the intestinal environment: A double-blind, placebo-controlled study.
- 2024-03
- Behavioural brain research 460
- PubMed: 38128887
- DOI: 10.1016/j.bbr.2023.114820
Study Design
- Type
- Randomized Controlled Trial (RCT)
- Population
- humans
- Methods
- randomized controlled trial, 6 weeks of 20 billion cells/day Bifidobacterium breve M-16 V, near-infrared spectroscopy (NIRS) assessments
We conducted a randomized controlled trial to investigate the potential of Bifidobacterium breve M-16 V to improve mood in humans. In this evaluation, we incorporated the use of near-infrared spectroscopy (NIRS), which has been used to evaluate mood states in studies with small sample sizes. Participants were given B. breve M-16 V (20 billion cells/day) for 6 weeks, and their mood state was assessed before and after ingestion. NIRS data were collected at rest and during a mental arithmetic task (under stress). Intake of B. breve M-16 V decreased the heart rate under stress and increased levels of the GABA-like substance pipecolic acid in stool samples. In addition, B. breve M-16 V improved mood and sleep scores in participants with high anxiety levels. These results suggest that B. breve M-16 V affects the metabolites of the gut microbiota and has the potential to modulate the autonomic nervous system and to improve mood and sleep.
Research Insights
| Supplement | Dose | Health Outcome | Effect Type | Effect Size | Source |
|---|